Current use of traditional NSAIDs and COX-2 inhibitors was associated with a modest increased risk of AMI/CHD, though most confidence intervals included the null value (e.g., rofecoxib OR 1.32; 95% CI 0.91-1.91).
Case-Control (n=364,658)
Does the use of traditional NSAIDs and COX-2 inhibitors increase the risk of hospitalized AMI and out-of-hospital CHD deaths in adults aged 40-84 years?
The study demonstrates a modest, though largely non-statistically significant, increased risk of AMI/CHD with both traditional NSAIDs and COX-2 inhibitors, suggesting that differentiating between the two classes is not a reliable tool for predicting cardiovascular risk.
Odds Ratio: 1.32 (95% CI 0.91–1.91)
BACKGROUND: Meta-analyses of observational studies show variability in the risk of acute myocardial infarction (AMI) among non-steroidal anti-inflammatory drugs (NSAIDs), with an increase in risk for rofecoxib and diclofenac, and no increase in risk for celecoxib, naproxen, or ibuprofen. METHODS AND RESULTS: We identified a cohort of 364 658 individuals aged 40-84 years who were enrolled in Saskatchewan Health, Canada, from 15 November 1999 to 31 December 2001. A nested case-control analysis compared 3252 incident cases of hospitalized AMI and out-of-hospital CHD deaths with 20 002 controls randomly sampled from the cohort. The incidence of AMI/CHD was 5.1 per 1000 person-years (95%CI: 5.0-5.3). The adjusted ORs (95%CI) of AMI/CHD in current users of individual NSAIDs compared with non-use were: celecoxib (1.11; 0.84-1.47), rofecoxib (1.32; 0.91-1.91), diclofenac (1.02; 0.75-1.38), naproxen (1.57; 0.98-2.52), ibuprofen (1.59; 0.88-2.89), and indomethacin (1.34; 0.81-2.19). Long-term use of rofecoxib was compatible with an increased risk (OR = 1.46; 0.97-2.22) while estimates of other individual NSAIDs were close to unity. Overall NSAID use was associated with a 30% increased risk of nonfatal AMI but was absent for fatal AMI/CHD. CONCLUSIONS: This study showed a modest increased risk of AMI/CHD with various traditional NSAIDs and COX-2 inhibitors. Confidence intervals of estimated ORs included the null value for most comparisons. The study confirmed that the differentiation between traditional NSAIDs and COX-2 inhibitors is not a reliable tool for predicting cardiovascular risk associated with NSAIDs.
Varas‐Lorenzo et al. (Fri,) conducted a case-control in Acute myocardial infarction (AMI) and coronary heart disease (CHD) (n=364,658). NSAIDs and COX-2 inhibitors vs. non-use was evaluated on Hospitalized AMI and out-of-hospital CHD deaths (OR 1.32, 95% CI 0.91-1.91). Current use of traditional NSAIDs and COX-2 inhibitors was associated with a modest increased risk of AMI/CHD, though most confidence intervals included the null value (e.g., rofecoxib OR 1.32; 95% CI 0.91-1.91).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: